Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00124891 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating GAP-486 in Non-sustained Ventricular Tachycardia
A Phase 2 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 500
- Enrollment target
NCT00124891: Clinical Trial Phase 2 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
NCT00124891 is a Phase 2 study that was terminated before completion, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 500 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (276% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00124891, a Phase 2 study, was terminated before completion, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 500 participants
- Enrollment target
Study Summary
To determine whether the administration of test article will decrease the occurrence of ventricular arrhythmias in patients who have acute coronary syndrome (unstable angina, ST segment elevated myocardial infarction or myocardial infarction without ST elevation).
Interventions
- DRUG Double-blind investigational anti-arrhythmic
- DRUG GAP-486
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2005-06-01 |
| Est. Completion | 2006-11-01 |
| Phase | Phase 2 |
Why NCT00124891 stopped before completion
NCT00124891 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (276% higher).
The record links to 0 conditions, and to 2 interventions - of which Double-blind investigational anti-arrhythmic is the first listed.
NCT00124891 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00124891 about?
NCT00124891 is a clinical study titled "Study Evaluating GAP-486 in Non-sustained Ventricular Tachycardia". To determine whether the administration of test article will decrease the occurrence of ventricular arrhythmias in patients who have acute coronary syndrome (unstable angina, ST segment elevated myocardial infarction or myocardial infarction without ST elevation).
What is the current status of trial NCT00124891?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 500 participants. The study started on 2005-06-01. Estimated completion is 2006-11-01.
What interventions are being tested in trial NCT00124891?
The interventions under investigation include: Double-blind investigational anti-arrhythmic (DRUG), GAP-486 (DRUG).
Who is sponsoring clinical trial NCT00124891?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00124891's enrollment target sits among peer trials
500 70th of 2000 higher than 1,927 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI